TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03117790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Study: NCT00835640
Drug: ALLEGRA® 180 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 180 mg
Study: NCT03193814
Drug: Chemotherapy + Apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
Study: NCT00274898
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04347473
Drug: Ilumya Injectable Product
Normalized name: Ilumya Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-23 injection
Study: NCT02975011
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study: NCT02241811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel without 3% Sodium Pentaborate Pentahydrate
Study: NCT00364572
Drug: placebo (control procedure)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of epidural saline 2 weeks apart
Study: NCT00664313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given daily for 112 doses (16 weeks)
Study: NCT01725230
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20-mg tablet
Study: NCT01725230
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-mg tablet
Study: NCT00940095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of placebo-matching clazosentan
Study: NCT02664051
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg 4x2 daily mannitol
Study: NCT00066469
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
Study: NCT04092907
Drug: HBM9036 0.25% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT04092907
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT00864669
Drug: CLUCOPHAGE® XR 500 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT01955434
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00394901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
Study: NCT01467115
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
Study: NCT01467115
Drug: Erythropoetin
Normalized name: Erythropoetin zeta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous or intravenous
Study: NCT01467115
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
Study: NCT02076399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet PO bid (morning and evening) over the course of 24 weeks
Study: NCT01480713
Drug: Isentress® (Raltegravir, 400 mg every 12 hours)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
Study: NCT01480713
Drug: Isentress® (Raltegravir, 400 every 12 hours)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
Study: NCT01840774
Drug: Low-dose pain medication (Ketalar) and saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02720601
Drug: Irinotecan & Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
Study: NCT03080545
Drug: Enstilar 0.005%-0.064% Topical Foam
Normalized name: Enstilar 0.005%-0.064% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical foam
Study: NCT02279719
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Study: NCT02279719
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Study: NCT00002955
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002955
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03817463
Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Study: NCT01559259
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
Study: NCT01559259
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
Study: NCT01559259
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
Study: NCT01559259
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two caplets of ibuprofen 200 mg
Study: NCT01559259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two caplets of placebo
Study: NCT00355537
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustanon- intramuscular testosterone 200mg every 2 weeks
Study: NCT00355537
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection intramuscular every 2 weeks
Study: NCT01159171
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
Study: NCT00896363
Drug: GSK163090 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developed for the treatment of Major Depressive Disorder
Study: NCT00896363
Drug: GSK163090 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developed for the treatment of Major Depressive Disorder
Study: NCT00896363
Drug: GSK163090 3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developed for the treatment of Major Depressive Disorder
Study: NCT00121524
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 1 mg is given iv. every 3 min during CPR
Study: NCT02759107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03504982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
Study: NCT00062023
Drug: Acetylsalicylic acid (Aspirin)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive oral aspirin once daily for 12 months.
Study: NCT00062023
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive oral sulindac twice daily for 12 months.
Study: NCT00395291
Drug: MK-0677
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
Study: NCT00395291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03691818
Drug: X0002 Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
Study: NCT03691818
Drug: Ibuprofen Tablet
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen Tab 400mg, tid.
Study: NCT03691818
Drug: Ibuprofen Placebo Tab
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen Placebo Tab 400mg, tid.
Study: NCT03691818
Drug: X0002 Placebo Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
Study: NCT00989521
Drug: PUR003
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR003 for inhalation
Study: NCT00989521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline for inhalation
Study: NCT00785421
Drug: only chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: observation, no treatment with LMWH
Study: NCT00074529
Drug: MK0677
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01242306
Drug: intracoronary infusion of acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
Study: NCT03638908
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03452917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 patients will 2 ml of normal saline
Study: NCT02567370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00657839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03860012
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
Study: NCT02200328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
Study: NCT02966093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
Study: NCT02976766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo three times a day for 10 days.
Study: NCT00191724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV), one infusion, over 12 hours
Study: NCT00873535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
Study: NCT01611363
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01611363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02958436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01529515
Drug: PP3M 175 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT01529515
Drug: PP3M 263 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT01135186
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sapropterin dihydrochloride: 10mg/kg/day
Study: NCT01529515
Drug: PP3M 350 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT01529515
Drug: PP3M 525 mg eq.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT01529515
Drug: Placebo (20% Intralipid emulsion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study: NCT03920293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Study: NCT00544453
Drug: [123I] MNI-308
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of \[123I\] MNI-308 and SPECT scanning
Study: NCT03100916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02568098
Drug: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
Study: NCT02568098
Drug: DHA-PQP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 6: DHA-PQP
Study: NCT01338350
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, suspension
Study: NCT01338350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, solution
Study: NCT02845908
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Study: NCT02845908
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin plus Leucovorin plus 5-FU
Study: NCT02845908
Drug: FOLFOX plus PAC(ip)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX plus intraperitoneally PAC
Study: NCT04170530
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT02022215
Drug: ME1111 Solution, Low strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME1111 Solution, Low strength, applied once daily for 48 weeks
Study: NCT02022215
Drug: ME1111 Solution, High strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME1111 Solution, High strength, applied once daily for 48 weeks
Study: NCT02022215
Drug: Matching Vehicle Solution
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Vehicle Solution, applied once daily for 48 weeks
Study: NCT02443194
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: after randomization the patient will receive cymbalta/ placebo for 3 months
Study: NCT00092703
Drug: MK0663, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092703
Drug: Comparator: Diclofenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02557958
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
Study: NCT02557958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
Study: NCT03770728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT01065194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
Study: NCT04767178
Drug: Ibuprofen (Sanofi, Istanbul, Turkey)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Study: NCT00580580
Drug: PESDA
Normalized name: Perfluorocarbon-Exposed Sonicated Dextrose Albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injections dosage 0.05-0.20 mL
Study: NCT01513603
Drug: CLAG-M
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV times 5 days
Study: NCT01513603
Drug: CLAG-M
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04315792
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo for 3 weeks
Study: NCT02349607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placeco
Study: NCT02349607
Drug: ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600 mg
Study: NCT01318278
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
Study: NCT02281786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to RO6926496
Study: NCT02281786
Drug: RO6926496
Approvals — FDA: no, EMA: no, PMDA: no
Description: single, ascending dose, intravenous administration
Study: NCT01327053
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Study: NCT04278950
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be 2.5mL of saline with brown food coloring.
Study: NCT04610476
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone oral 1-5 mg/day
Study: NCT04610476
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
Study: NCT01574157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
Study: NCT02480166
Drug: 8 weeks SOF/LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.